We are stepping outside the conventional approach to developing cancer immunotherapies by using our Translational Science Platform to prioritize targets and identify related biomarkers to match the right therapy to the right patients, thereby enabling enriched trial designs, which we believe will lead to shortened development timelines.
Our lead program, JTX-2011 – an ICOS agonist monoclonal antibody - complements existing cancer immunotherapies, such as anti-PD-1 therapies, by binding to and activating ICOS, stimulating an immune response against the cancer.
We are also developing treatments that target other immune cells – "Beyond T cells" – in order to help patients whose tumors are driven by mechanisms, such as immune-suppressive macrophages.
our SCIENCE
First cancer vaccine developed (Coley's "toxins")
Coley’s work first published. In the late 19th century, William Coley injected bacterial extracts into multiple patients suffering from bone or soft tissue sarcomas and over several decades reported responses or complete remissions in a substantial fraction of them (Cell, 2015)
Immunotherapy largely dismissed as a viable avenue to treat cancer
Co-stimulatory pathways on T cells described by Peter Linsley, Jim Allison and Jeffrey Bluestone
PD-1 receptor (immune checkpoint) identified by Tasuku Honjo
IFN-α approved as adjuvant therapy (additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back)
Preclinical evidence from Jim Allison of enhanced anti-tumor immunity by CTLA-4 published in Science
Learn More
Brad Carthon and Jounce founders Pam Sharma & Jim Allison’s publication on enhanced survival related to up-regulation of ICOS on T cells in Clinical Cancer Research
Learn More
Yervoy® anti-CTLA-4 approved for advanced melanoma
Jounce launched by Third Rock Ventures and founders, James P. Allison, Ph.D., Thomas F. Gajewski, M.D., Ph.D., Drew Pardoll, M.D., Ph.D, Robert Schreiber, Ph.D, Padmanee Sharma, M.D., Ph.D., Louis M. Weiner, M.D.
Jounce expands application of translational science platform to Beyond T cells and initiates series of programs targeting myeloid and other cell types
Keytruda® and Opdivo® (Anti-PD-1), (immune checkpoint therapies) approved; additional clinical trials indicate activity in several cancers
Jounce declares first development candidate, JTX-2011, an agonist mAb targeting ICOS
Jounce founder, Jim Allison receives the Lasker-DeBakey Clinical Medical Research Award
"We have a fantastic group of scientists who have specialized knowledge in the field and are highly collaborative. Each person brings something unique to the table, but together we can do amazing things."
- Tyler Simpson, Senior Scientist, TME Group
"We feel united by a common purpose. Jounce is not just another follow-on drug discovery company – the people at Jounce are pioneers who are truly focused on making a difference for patients."
- Todd Rowe, Informatics Manager, IT & Informatics
We are looking for exceptional individuals who share our passion and perseverance for developing highly durable cancer immunotherapies that dramatically impact and improve patients' lives
